Carvolix secures €30m debt financing from Claret Capital Partners
Carvolix, the Aix-en-Provence-based medical technology company formerly known as Affluent Medical, has secured a €30 million debt financing from Claret Capital Partners to accelerate the commercialisation of its AI-driven cardiac and neurovascular portfolio. The deal, structured as a growth loan rather than an equity raise, allows existing shareholders to avoid dilution while giving the company capital to push its lead product, TAVIpilot, into broader clinical and commercial use.
TAVIpilot is an AI-guided intraoperative software platform designed to assist interventional cardiologists during transcatheter aortic valve implantation (TAVI) procedures. The system received FDA clearance and is positioned by the company as a tool to reduce the procedural complexity that currently limits access to TAVI. Carvolix is also developing biomimetic heart valves and mini-robotic systems aimed at expanding thrombectomy access in ischaemic stroke patients.
The case for AI-guided procedural support
The clinical need framing in the announcement is striking. Carvolix cites figures suggesting that 1.7 million patients per year are eligible for TAVI procedures globally, yet only 17 per cent currently receive the intervention. In ischaemic stroke, the company says fewer than 5 per cent of patients worldwide have access to mechanical thrombectomy. Both figures point to a bottleneck driven by procedural complexity and specialist-operator dependency rather than by a shortage of candidates or approved devices.
Chief executive Sébastien Ladet said the financing provides "specific means directed towards the commercialisation of TAVIpilot and preparation of industrialisation across our portfolio," adding that Claret Capital's involvement represents further validation of Carvolix's technology roadmap. Joey Mason, Life Sciences Venture Partner at Claret, described the company as "an exciting business with a technology portfolio which could transform the lives of people" facing complex cardiovascular and neurovascular procedures, though neither executive provided specific revenue targets or deployment timelines.
Market context and competitive landscape
The structural heart market is one of the most actively funded segments in medtech, dominated by established players such as Edwards Lifesciences and Medtronic, whose TAVI platforms have already captured substantial market share in high-volume centres. The opportunity for an AI-guided software overlay is to extend procedural capability to lower-volume or less-specialised centres, a proposition that several digital health and surgical robotics companies are pursuing in parallel across cardiovascular and other complex-procedure markets.
Claret Capital, which describes itself as Europe's largest independent growth debt fund manager, has been increasing its exposure to listed and late-stage European life sciences companies. Its recent portfolio additions include Inventiva, Cinclus Pharma, SIS Medical, and Abivax. The Carvolix deal follows that pattern: a commercial- or near-commercial-stage company seeking non-dilutive capital to bridge from regulatory clearance to meaningful revenue. Growth lending of this kind has become an increasingly common instrument for European medtech and biotech companies looking to preserve equity ahead of a potential partnership or exit.
For Carvolix, the near-term milestones to watch are the pace of TAVIpilot commercial rollout across European and US cardiac centres, clinical data on procedure time and outcome consistency that would underpin reimbursement discussions, and progress on the broader robotics and biomimetics pipeline. The company's stock trades on Euronext Paris under the ticker CVX.